

**Antimicrobial Susceptibility Test Results for Gram-positive isolates recovered from all sites: 2021**

Organism Name	Antibiotics in common use (1st line reporting)										Reserved	Topical
	Number tested	Ampicillin/ amoxicillin	Penicillin	Meth/Flucloxacillin	Erythromycin	Clindamycin #	Gentamicin	Nitrofurantoin <sup>d</sup>	Trimethoprim <sup>d</sup>	Trimethoprim + sulfamethoxazole	Ciprofloxacin #	Chloramphenicol
<i>S. aureus</i> (not MRSA)	588		20	100 <sup>a</sup>	94	95	99			100	99	99
MRSA	24		0	0	96	100	91			100		
<i>S. saprophyticus</i>	59	98		98			98	97	97			
<i>Enterococcus faecalis/spp</i> <sup>b</sup>	61	100					98					
Streptococcus Grp A	2											
<i>Enterococcus faecium</i>	3											
<i>Streptococcus pneumoniae</i>	9											

**Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from all sites: 2021**

Organism Name	Antibiotics in common use (1st line reporting)									Reserved (2nd line reporting)			
	Number tested	Ampicillin/ amoxicillin	Amoxicillin-Clavulanate	Cefuroxime IV	Cefalexin <sup>d</sup>	Nitrofurantoin <sup>d</sup>	Trimethoprim <sup>d</sup>	Trimethoprim + sulfamethoxazole	Tetracycline	Ceftriaxone	Ciprofloxacin #	Meropenem #	Piperacillin-Tazobactam <sup>s</sup>
<i>Escherichia coli</i>	709	65	77	99	97	100	84	86		98	98		
ESCAPM group	22	0	0	0				100		100	100		
<i>Klebsiella oxytoca</i>	31	0	100	100	96		97	97		100	97		
<i>Klebsiella pneumoniae</i>	39	0	81				73	86		95	91		
<i>Proteus mirabilis</i>	31	94	100	97	93		83	94		100	100		
<i>Haemophilus influenzae</i>	24	71	86	80									
<i>Pseudomonas aeruginosa</i>	40												
ESCM group: <i>Enterobacter spp</i> , <i>Serratia marcescens</i> , <i>Citrobacter spp</i> , <i>Morganella morganii</i>										85	94	100	

<sup>a</sup> *S. aureus* susceptible to methicillin/flucloxacillin denotes susceptibility to ceftazidime and amoxicillin-clavulanate

<sup>b</sup> *Enterococcus* species are intrinsically resistant to cephalosporins

<sup>c</sup> Includes Intermediate (Susceptible, Increased Exposure) results

<sup>d</sup> Treatment of uncomplicated urinary tract infections only

# Use requires patient-specific Infectious Diseases/Clinical Microbiology approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g. 'The Pink Book'.

\$ Use requires patient-specific Infectious Diseases/Clinical Microbiology/Respiratory Specialist approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g. 'The Pink Book'.

No data or not tested
Colour Interpretation
≥ 90% Susceptible
70 - 89% Susceptible
< 70% Susceptible